MANE
Veradermics, Incorporated NYSE Listed Feb 4, 2026$102.42
Pre-mkt
$103.50
+1.05%
Mkt Cap $4.3B
52w Low $32.00
71.0% of range
52w High $131.24
50d MA $107.34
200d MA $87.81
P/E (TTM)
—
EV/EBITDA
—
P/B
377.2x
Debt/Equity
0.0x
ROE
57.8%
P/FCF
-870.5x
RSI (14)
49.30
ATR (14)
$4.64
Beta
0.00
50d MA
$107.34
200d MA
$87.81
Avg Volume
620.2K
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
470 James Street · New Haven, CT 06513 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AMC | -0.65 | -0.64 | +1.5% | 108.95 | -0.7% | +0.1% | +1.8% | +1.5% | -4.0% | +2.9% | — |
| May 12, 2026 | AMC | -0.56 | -1.32 | -135.7% | 103.90 | +0.1% | +3.1% | -1.0% | -6.0% | +0.7% | -0.3% | — |
| Mar 30, 2026 | AMC | -1.81 | -1.06 | +41.5% | 60.85 | +1.0% | +3.8% | -6.9% | +9.2% | -0.6% | -11.1% | — |
| Feb 25, 2026 | AMC | -1.81 | -1.62 | +10.3% | 42.17 | +0.0% | +1.8% | +6.9% | +1.7% | -3.3% | +5.0% | — |
| Dec 3, 2025 | AMC | — | -1.62 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 15 | B. Riley Securities | Initiates | Buy | $170 | $110.17 | $118.75 | +7.8% | +12.3% | -14.4% | +5.2% | -4.7% | +3.3% |
| Jun 2 | Needham | Initiates | Buy | $136 | $101.51 | $101.51 | +0.0% | -3.3% | -1.5% | +4.6% | -9.4% | -1.5% |
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $73.35 | $75.05 | +2.3% | -4.1% | -1.5% | -2.0% | +47.6% | +3.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Waldman Reid AlexanderDir/Off | Chief Executive Officer | Sell | 249 | $111.28 | $28K | 170,824 | -0.07% | +3.95% |
| Aug 17, 2026 | Waldman Reid AlexanderDir/Off | Chief Executive Officer | Sell | 3,000 | $109.38 | $328K | 171,073 | -0.07% | +3.95% |
| Aug 17, 2026 | Waldman Reid AlexanderDir/Off | Chief Executive Officer | Sell | 27,490 | $108.45 | $3.0M | 174,073 | -0.07% | +3.95% |
| Aug 17, 2026 | Waldman Reid AlexanderDir/Off | Chief Executive Officer | Sell | 25,234 | $107.53 | $2.7M | 201,563 | -0.07% | +3.95% |
| Aug 17, 2026 | Waldman Reid AlexanderDir/Off | Chief Executive Officer | Sell | 11,527 | $106.72 | $1.2M | 226,797 | -0.07% | +3.95% |
| Aug 17, 2026 | Durso Timothy AugustOff | Chief Technical Officer | Sell | 161 | $111.28 | $18K | 78,142 | -0.07% | +3.95% |
| Aug 17, 2026 | Durso Timothy AugustOff | Chief Technical Officer | Sell | 2,348 | $109.34 | $257K | 78,303 | -0.07% | +3.95% |
| Aug 17, 2026 | Durso Timothy AugustOff | Chief Technical Officer | Sell | 16,767 | $108.38 | $1.8M | 80,651 | -0.07% | +3.95% |
| Aug 17, 2026 | Durso Timothy AugustOff | Chief Technical Officer | Sell | 16,306 | $107.52 | $1.8M | 97,418 | -0.07% | +3.95% |
| Aug 17, 2026 | Durso Timothy AugustOff | Chief Technical Officer | Sell | 7,918 | $106.71 | $845K | 113,724 | -0.07% | +3.95% |
8-K · 2.02
!! High
Veradermics, Incorporated -- 8-K 2.02: Earnings Results
Veradermics reported Q2 2026 earnings on August 11, 2026, providing investors with updated financial performance metrics for the quarter ending June 30, 2026.
Aug 11
8-K · 8.01
!! High
Veradermics, Incorporated -- 8-K 8.01: Material Event / Announcement
Veradermics' VDPHL01 oral minoxidil showed positive Phase 2 results in hair loss patients, demonstrating efficacy and safety for potential female pattern hair loss treatment advancement.
Jul 15
8-K · 1.01
!! High
Veradermics, Incorporated -- 8-K 1.01: Material Agreement
I don't have enough information from this truncated summary to provide a meaningful analysis. The summary appears incomplete ("THE HOLDER HEREBY IRREVOCAB..."). Please provide the full summary for an accurate investor explanation.
May 1
8-K
Veradermics, Incorporated -- 8-K Filing
I cannot provide a meaningful investor analysis as the filing summary lacks substantive information about Veradermics' business developments, financial results, or material events.
Apr 27
8-K · 8.01
!! High
Veradermics, Incorporated -- 8-K 8.01: Material Event / Announcement
Veradermics announced positive Phase 2/3 data for VDPHL01 treating male pattern hair loss, potentially advancing the treatment toward regulatory approval and market commercialization.
Apr 27
8-K
Unknown — 8-K Filing
MANE's multiple late-stage pipeline catalysts in 2024—including two Phase 3 readouts and potential NDA submission—offer significant upside if successful, justifying investor patience with clinical execution risk.
Mar 30
8-K · 5.03
! Medium
Veradermics, Incorporated -- 8-K 5.03: Amendment to Articles / Bylaws
Veradermics, Incorporated changed its fiscal year end, which may affect the timing of financial reporting and earnings announcements for investors monitoring MANE stock.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 3,755,550 | $462M | Added | Jun 2026 |
| 2 | Deep Track Capital, Lp | 2,000,000 | $246M | New | Jun 2026 |
| 3 | Siren, L.l.c. | 1,655,374 | $204M | New | Jun 2026 |
| 4 | Blackrock, Inc. | 1,593,791 | $196M | New | Jun 2026 |
| 5 | Viking Global Investors Lp | 1,561,494 | $192M | Reduced | Jun 2026 |
| 6 | Aberdeen Group Plc | 1,096,642 | $135M | Added | Jun 2026 |
| 7 | D. E. Shaw & Co., Inc. | 1,013,643 | $125M | Added | Jun 2026 |
| 8 | Fmr Llc | 1,792,909 | $113M | New | Mar 2026 |
| 9 | Vanguard Capital Management Llc | 869,212 | $107M | Added | Jun 2026 |
| 10 | Maverick Capital Ltd | 789,980 | $97M | New | Jun 2026 |
| 11 | Jennison Associates Llc | 748,678 | $92M | New | Jun 2026 |
| 12 | Infinitum Asset Management, Llc | 731,149 | $90M | New | Jun 2026 |
| 13 | Jpmorgan Chase & Co | 976,166 | $59M | New | Mar 2026 |
| 14 | Marshall Wace, Llp | 654,601 | $41M | New | Mar 2026 |
| 15 | Emerald Advisers, Llc | 288,370 | $35M | New | Jun 2026 |
| 16 | Woodline Partners Lp | 500,646 | $32M | New | Mar 2026 |
| 17 | Emerald Mutual Fund Advisers Trust | 209,924 | $26M | New | Jun 2026 |
| 18 | Ubs Group Ag | 347,075 | $22M | New | Mar 2026 |
| 19 | Vivo Capital, Llc | 300,000 | $19M | New | Mar 2026 |
| 20 | Vanguard Portfolio Management Llc | 149,054 | $18M | Added | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$4.28B
Enterprise Value
$20.57B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-4.04x
P/B
377.24x
P/S
—
P/FCF
-870.51x
EV/EBITDA
—
Shares Out
201.3M
Financials (TTM)
Revenue
$0
Net Income
-$78.2M
EBITDA
-$83.5M
Free Cash Flow
-$23.7M
Op Cash Flow
-$23.7M
EPS Basic
$-0.14
EPS Diluted
$-2.17
EPS Forward
$-2.65
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$59.4M
Total Liab.
$4.7M
Total Equity
$54.7M
Cash
$53.1M
LT Debt
$0
Book Value/Sh
$0.27
Debt/Equity
0.00x
Current Ratio
11.77
Quick Ratio
11.77
Returns & Growth
ROE
57.8%
ROA
-45.9%
ROIC
-49.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-70.9%
Price Returns
2W
+5.0%
1M
-5.4%
3M
+11.5%
6M
+67.7%
12M
+171.3%
Technicals
52W High
$131.24
52W Low
$32.00
50d MA
$107.34
200d MA
$87.81
RSI (14)
49.30
ATR (14)
$4.64
Beta
0.00
Avg Volume
620K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$75.00
High
$75.00
Low
$75.00
Median
$75.00
Data updated apr 25, 2026 8:30pm
· Source: financialmodelingprep.com